logo

COVID-19: Drugs in Development

Share

The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Drug
Current Stage
Next Milestone
Collaboration
Last Updated
Ocugen, Inc.
(OCGN)
COVAXIN
Second interim analysis of the Phase 3 study of Covaxin showed 78% efficacy after the second dose in preventing Covid-19; 100% in severe Covid-19; and 70% in asymptomatic Covid-19 infection.
-
Bharat Biotech
04/22/2021
Johnson & Johnson
(JNJ)
Covid-19 Vaccine
The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) confirmed that the vaccine's overall benefit-risk profile remains positive; The company to resume vaccine rollout.
-
-
04/21/2021
Tonix Pharmaceuticals Holding Corp.
(TNXP)
TNX-3500
Tonix Pharma in worldwide licensing agreement with OyaGen, Inc. to develop TNX-3500, an antiviral SARS-CoV-2 inhibitor, to treat Covid-19.
-
OyaGen, Inc.
04/20/2021
Eli Lilly And Co.
(LLY)
LY-CoV555, also known as Bamlanivimab
LY-CoV555 an antibody therapeutic is being developed for treatment and prevention of COVID-19.

Phase 3 trial OF LY-CoV555 for the prevention of SARS-CoV-2 infection and COVID-19 (BLAZE-2)

On Nov.9, 2020, FDA issued emergency use authorization for Bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients.
-
AbCellera Biologics Inc., National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center
04/19/2021
Cyclica
capmatinib- Repurposed
Announced capmatinib showed robust antiviral effects in experimental Covid-19 models.
-
Ryerson University
The Vector Institute
04/15/2021
Adagio Therapeutics, Inc.
ADG20
Started Phase 1/2/3 study in high-risk people with mild to moderate COVID-19.
Phase 2/3 study to start in the second half of 2021.
-
04/14/2021
Eli Lilly And Co.
(LLY)
LY-CoV555, also known as Bamlanivimab
Phase 2 trial of LY3819253, alone or in combination with either LY3832479 or VIR-7831 in low-risk adults with COVID-19 (BLAZE-4) began in Jan.2020
-- Positive results from BLAZE-4 trial reported on Mar.29,2021
-
Vir Biotechnology and GSK
04/09/2021
DYADIC INTERNATIONAL INC
(DYAI)
DYAI-100
DYAI-100 advancing towards first-in-human Phase 1 clinical trial
-
-
04/09/2021

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
Walt Disney World, the Orlando, Florida-based entertainment complex, is easing the health safety guidelines that were rolled out to prevent the spread of the ongoing COVID-19 pandemic. The complex is ending temperature checks in a phased manner following the advice of the Centers for Disease Control and Prevention (CDC) and local health officials. Frito-Lay North America, the convenient foods division of food and beverages giant PepsiCo, Inc., is recalling select Ruffles All Dressed Potato Chips citing the possible presence of undeclared milk ingredients, a known allergen, the U.S. Food and Drug Administration said. According to the agency, the recalled products may have distributed regionally to Walmart's Sam's Club Warehouses. Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced Friday that they have initiated the Biologics License Application (BLA) process with the U.S. Food and Drug Administration (FDA) for approval of their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The companies initiated...